Study of Full-Body Photobiomodulation Therapy Effects on Blood Pressure and Artery Health in Adults with Hypertension Aged 40 to 60

What this Trial Is About

Researchers are conducting a randomized, double-blind, sham-controlled clinical trial to compare the immediate effects of two types of photobiomodulation PBM therapies on blood pressure, endothelial function, and arterial stiffness in people with hypertension. The study includes participants aged 40 to 60 years who have been diagnosed with hypertension for at least 3 months and are using blood pressure medications. The goal is to better understand how these light-based therapies may influence cardiovascular measures in this population. Participants will be randomly assigned to one of four groups full-body PBM from an LED panel, sham panel treatment with the device turned off, modified intravascular laser irradiation of blood ILIB therapy, or sham ILIB treatment with the device turned off. Each participant will receive a single application of the assigned therapy. The LED panel uses a wavelength of 660 nm with specific energy and power settings, while the modified ILIB also uses 660 nm but with different energy and power characteristics. Before and after the intervention, participants will be assessed for blood pressure, endothelial function, arterial stiffness, blood nitrite levels, and skin thermography. Ambulatory blood pressure monitoring will be performed after the intervention to track blood pressure over 24 hours. The primary outcome is the diastolic blood pressure effect immediately and up to 24 hours post-treatment. Secondary outcomes include systolic and mean arterial pressure, endothelial function, arterial stiffness, and blood nitrite changes measured at specified times after the therapy. Data analysis will determine if the therapies have significant acute effects on these cardiovascular parameters.

Acute Effect of Photobiomodulation in Individuals with Hypertension